SrasV1, PubMed, Curation, bibRecord, 002134

Human neutralizing Fab molecules against severe acute respiratory syndrome coronavirus generated by phage display.

Identifieur interne : 002134 ( PubMed/Curation ); précédent : 002133; suivant : 002135

Human neutralizing Fab molecules against severe acute respiratory syndrome coronavirus generated by phage display.

Auteurs : Xiaoping Kang [République populaire de Chine] ; Bao-An Yang ; Yuyang Hu ; Hui Zhao ; Wei Xiong ; Yinhui Yang ; Bingyin Si ; Qingyu Zhu

Source :

Clinical and vaccine immunology : CVI [ 1556-6811 ] ; 2006.

RBID : pubmed:16893997

Descripteurs français

English descriptors

KwdEn :
- Amino Acid Sequence, Antibodies, Viral (genetics), Antibodies, Viral (immunology), Antibodies, Viral (isolation & purification), Humans, Immunoglobulin Fab Fragments (genetics), Immunoglobulin Fab Fragments (immunology), Immunoglobulin Fab Fragments (isolation & purification), Immunoglobulin Variable Region (immunology), Immunologic Factors (chemistry), Immunologic Factors (immunology), Microbial Sensitivity Tests, Molecular Sequence Data, Peptide Library, Reverse Transcriptase Polymerase Chain Reaction, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology).
MESH :
- chemical , chemistry : Immunologic Factors.
- chemical , genetics : Antibodies, Viral, Immunoglobulin Fab Fragments.
- chemical , immunology : Antibodies, Viral, Immunoglobulin Fab Fragments, Immunoglobulin Variable Region, Immunologic Factors.
- chemical , isolation & purification : Antibodies, Viral, Immunoglobulin Fab Fragments.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- Amino Acid Sequence, Humans, Microbial Sensitivity Tests, Molecular Sequence Data, Peptide Library, Reverse Transcriptase Polymerase Chain Reaction.

Abstract

Human recombinant Fab fragments specific for the spike protein of severe acute respiratory syndrome coronavirus (SARS-CoV) were screened from a human Fab library, which was generated from RNAs from peripheral lymphocytes of convalescent SARS patients. Among 50 randomly picked clones, 12 Fabs specially reacted with S protein by an enzyme-linked immunosorbent assay. The microneutralizing test showed that one clone, designated M1A, had neutralizing activity on Vero E6 cells against SARS-CoV. DNA sequence analysis indicated that the light- and heavy-chain genes of M1A Fab belong to the kappa2a and 4f families, respectively. A neutralizing test on purified M1A demonstrated that 0.5 mg/ml of M1A completely inhibited SARS-CoV activity, with an absence of cytopathic effect for 7 days. Real-time fluorescence reverse transcription-PCR also proved the neutralizing capacity of M1A. These data showed that the number of virus copies was significantly reduced in the M1A-treated group, suggesting an important role for M1A in passive immunoprophylaxis against the SARS virus.

DOI: 10.1128/CVI.00037-06
PubMed: 16893997

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002134

Links to Exploration step

pubmed:16893997

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Human neutralizing Fab molecules against severe acute respiratory syndrome coronavirus generated by phage display.</title>
<author><name sortKey="Kang, Xiaoping" sort="Kang, Xiaoping" uniqKey="Kang X" first="Xiaoping" last="Kang">Xiaoping Kang</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Yang, Bao An" sort="Yang, Bao An" uniqKey="Yang B" first="Bao-An" last="Yang">Bao-An Yang</name>
</author>
<author><name sortKey="Hu, Yuyang" sort="Hu, Yuyang" uniqKey="Hu Y" first="Yuyang" last="Hu">Yuyang Hu</name>
</author>
<author><name sortKey="Zhao, Hui" sort="Zhao, Hui" uniqKey="Zhao H" first="Hui" last="Zhao">Hui Zhao</name>
</author>
<author><name sortKey="Xiong, Wei" sort="Xiong, Wei" uniqKey="Xiong W" first="Wei" last="Xiong">Wei Xiong</name>
</author>
<author><name sortKey="Yang, Yinhui" sort="Yang, Yinhui" uniqKey="Yang Y" first="Yinhui" last="Yang">Yinhui Yang</name>
</author>
<author><name sortKey="Si, Bingyin" sort="Si, Bingyin" uniqKey="Si B" first="Bingyin" last="Si">Bingyin Si</name>
</author>
<author><name sortKey="Zhu, Qingyu" sort="Zhu, Qingyu" uniqKey="Zhu Q" first="Qingyu" last="Zhu">Qingyu Zhu</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:16893997</idno>
<idno type="pmid">16893997</idno>
<idno type="doi">10.1128/CVI.00037-06</idno>
<idno type="wicri:Area/PubMed/Corpus">002134</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002134</idno>
<idno type="wicri:Area/PubMed/Curation">002134</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002134</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Human neutralizing Fab molecules against severe acute respiratory syndrome coronavirus generated by phage display.</title>
<author><name sortKey="Kang, Xiaoping" sort="Kang, Xiaoping" uniqKey="Kang X" first="Xiaoping" last="Kang">Xiaoping Kang</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Yang, Bao An" sort="Yang, Bao An" uniqKey="Yang B" first="Bao-An" last="Yang">Bao-An Yang</name>
</author>
<author><name sortKey="Hu, Yuyang" sort="Hu, Yuyang" uniqKey="Hu Y" first="Yuyang" last="Hu">Yuyang Hu</name>
</author>
<author><name sortKey="Zhao, Hui" sort="Zhao, Hui" uniqKey="Zhao H" first="Hui" last="Zhao">Hui Zhao</name>
</author>
<author><name sortKey="Xiong, Wei" sort="Xiong, Wei" uniqKey="Xiong W" first="Wei" last="Xiong">Wei Xiong</name>
</author>
<author><name sortKey="Yang, Yinhui" sort="Yang, Yinhui" uniqKey="Yang Y" first="Yinhui" last="Yang">Yinhui Yang</name>
</author>
<author><name sortKey="Si, Bingyin" sort="Si, Bingyin" uniqKey="Si B" first="Bingyin" last="Si">Bingyin Si</name>
</author>
<author><name sortKey="Zhu, Qingyu" sort="Zhu, Qingyu" uniqKey="Zhu Q" first="Qingyu" last="Zhu">Qingyu Zhu</name>
</author>
</analytic>
<series><title level="j">Clinical and vaccine immunology : CVI</title>
<idno type="ISSN">1556-6811</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Antibodies, Viral (genetics)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Antibodies, Viral (isolation & purification)</term>
<term>Humans</term>
<term>Immunoglobulin Fab Fragments (genetics)</term>
<term>Immunoglobulin Fab Fragments (immunology)</term>
<term>Immunoglobulin Fab Fragments (isolation & purification)</term>
<term>Immunoglobulin Variable Region (immunology)</term>
<term>Immunologic Factors (chemistry)</term>
<term>Immunologic Factors (immunology)</term>
<term>Microbial Sensitivity Tests</term>
<term>Molecular Sequence Data</term>
<term>Peptide Library</term>
<term>Reverse Transcriptase Polymerase Chain Reaction</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps antiviraux (génétique)</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Anticorps antiviraux (isolement et purification)</term>
<term>Banque de peptides</term>
<term>Données de séquences moléculaires</term>
<term>Facteurs immunologiques ()</term>
<term>Facteurs immunologiques (immunologie)</term>
<term>Fragments Fab d'immunoglobuline (génétique)</term>
<term>Fragments Fab d'immunoglobuline (immunologie)</term>
<term>Fragments Fab d'immunoglobuline (isolement et purification)</term>
<term>Humains</term>
<term>RT-PCR</term>
<term>Région variable d'immunoglobuline (immunologie)</term>
<term>Syndrome respiratoire aigu sévère (immunologie)</term>
<term>Séquence d'acides aminés</term>
<term>Tests de sensibilité microbienne</term>
<term>Virus du SRAS (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Immunologic Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Antibodies, Viral</term>
<term>Immunoglobulin Fab Fragments</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term>
<term>Immunoglobulin Fab Fragments</term>
<term>Immunoglobulin Variable Region</term>
<term>Immunologic Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Antibodies, Viral</term>
<term>Immunoglobulin Fab Fragments</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Fragments Fab d'immunoglobuline</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Facteurs immunologiques</term>
<term>Fragments Fab d'immunoglobuline</term>
<term>Région variable d'immunoglobuline</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Fragments Fab d'immunoglobuline</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Humans</term>
<term>Microbial Sensitivity Tests</term>
<term>Molecular Sequence Data</term>
<term>Peptide Library</term>
<term>Reverse Transcriptase Polymerase Chain Reaction</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Banque de peptides</term>
<term>Données de séquences moléculaires</term>
<term>Facteurs immunologiques</term>
<term>Humains</term>
<term>RT-PCR</term>
<term>Séquence d'acides aminés</term>
<term>Tests de sensibilité microbienne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Human recombinant Fab fragments specific for the spike protein of severe acute respiratory syndrome coronavirus (SARS-CoV) were screened from a human Fab library, which was generated from RNAs from peripheral lymphocytes of convalescent SARS patients. Among 50 randomly picked clones, 12 Fabs specially reacted with S protein by an enzyme-linked immunosorbent assay. The microneutralizing test showed that one clone, designated M1A, had neutralizing activity on Vero E6 cells against SARS-CoV. DNA sequence analysis indicated that the light- and heavy-chain genes of M1A Fab belong to the kappa2a and 4f families, respectively. A neutralizing test on purified M1A demonstrated that 0.5 mg/ml of M1A completely inhibited SARS-CoV activity, with an absence of cytopathic effect for 7 days. Real-time fluorescence reverse transcription-PCR also proved the neutralizing capacity of M1A. These data showed that the number of virus copies was significantly reduced in the M1A-treated group, suggesting an important role for M1A in passive immunoprophylaxis against the SARS virus.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16893997</PMID>
<DateCompleted><Year>2006</Year>
<Month>12</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1556-6811</ISSN>
<JournalIssue CitedMedium="Print"><Volume>13</Volume>
<Issue>8</Issue>
<PubDate><Year>2006</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Clinical and vaccine immunology : CVI</Title>
<ISOAbbreviation>Clin. Vaccine Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Human neutralizing Fab molecules against severe acute respiratory syndrome coronavirus generated by phage display.</ArticleTitle>
<Pagination><MedlinePgn>953-7</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Human recombinant Fab fragments specific for the spike protein of severe acute respiratory syndrome coronavirus (SARS-CoV) were screened from a human Fab library, which was generated from RNAs from peripheral lymphocytes of convalescent SARS patients. Among 50 randomly picked clones, 12 Fabs specially reacted with S protein by an enzyme-linked immunosorbent assay. The microneutralizing test showed that one clone, designated M1A, had neutralizing activity on Vero E6 cells against SARS-CoV. DNA sequence analysis indicated that the light- and heavy-chain genes of M1A Fab belong to the kappa2a and 4f families, respectively. A neutralizing test on purified M1A demonstrated that 0.5 mg/ml of M1A completely inhibited SARS-CoV activity, with an absence of cytopathic effect for 7 days. Real-time fluorescence reverse transcription-PCR also proved the neutralizing capacity of M1A. These data showed that the number of virus copies was significantly reduced in the M1A-treated group, suggesting an important role for M1A in passive immunoprophylaxis against the SARS virus.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kang</LastName>
<ForeName>Xiaoping</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Bao-An</ForeName>
<Initials>BA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hu</LastName>
<ForeName>Yuyang</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhao</LastName>
<ForeName>Hui</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Xiong</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Yinhui</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Si</LastName>
<ForeName>Bingyin</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhu</LastName>
<ForeName>Qingyu</ForeName>
<Initials>Q</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Clin Vaccine Immunol</MedlineTA>
<NlmUniqueID>101252125</NlmUniqueID>
<ISSNLinking>1556-679X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007140">Immunoglobulin Fab Fragments</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007135">Immunoglobulin Variable Region</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019151">Peptide Library</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007140" MajorTopicYN="N">Immunoglobulin Fab Fragments</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007135" MajorTopicYN="N">Immunoglobulin Variable Region</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019151" MajorTopicYN="Y">Peptide Library</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year>
<Month>8</Month>
<Day>9</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2006</Year>
<Month>12</Month>
<Day>9</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2006</Year>
<Month>8</Month>
<Day>9</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16893997</ArticleId>
<ArticleId IdType="pii">13/8/953</ArticleId>
<ArticleId IdType="doi">10.1128/CVI.00037-06</ArticleId>
<ArticleId IdType="pmc">PMC1539127</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Vaccine. 2002 Jan 31;20(9-10):1281-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11818146</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2001 Jan 20;279(2):371-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11162792</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2002 Dec;40(12):4472-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12454138</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2004 May 21;304(5674):1097</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15155925</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2004 Sep 15;173(6):4050-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15356154</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 1984 Jul;20(1):128-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6086707</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1990 Dec 6;348(6301):552-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2247164</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):7978-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1896445</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 1991 Dec 5;222(3):581-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1748994</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9339-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1384050</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1993 Sep 25;268(27):20668-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8376416</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 1994 Sep;32(9):2331-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7529256</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Neuroimmunol. 1999 Feb 1;94(1-2):204-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10376954</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1999 Aug;80 ( Pt 8):1987-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10466795</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Feb;79(3):1743-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15650199</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Feb;79(3):1906-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15650214</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):797-801</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15642942</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viral Immunol. 2004;17(4):528-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15671749</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Sep;79(18):11638-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16140741</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2005 Sep 16;309(5742):1822-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16166506</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2005 Sep 16;309(5742):1864-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16166518</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Mol Immunol. 2004 Jun;1(3):193-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16219167</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2000 Apr;60(4):446-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10686029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2003 Jan;69(1):99-107</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12436484</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002134 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002134 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:16893997
   |texte=   Human neutralizing Fab molecules against severe acute respiratory syndrome coronavirus generated by phage display.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:16893997" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Human neutralizing Fab molecules against severe acute respiratory syndrome coronavirus generated by phage display.

Human neutralizing Fab molecules against severe acute respiratory syndrome coronavirus generated by phage display.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki